The cancer care platform developer secured funding in a series D round co-led by Merck Global Health Innovation Fund and backed by LabCorp.
Pharmaceutical firm Merck & Co has co-led a $26m series D round for US-based cancer care technology provider Navigating Cancer through its Merck Global Health Innovation (GHI) Fund.
The round was co-led by TT Capital Partners, part of healthcare merchant bank TripleTree, and included laboratory services provider LabCorp, Orix Growth Capital, Rustic Canyon Partners and BrightEdge, a fund overseen by the American Cancer Society.
Navigating Cancer’s Patient Relationship Management software helps care providers more effectively engage and communicate with cancer…
